Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2019 - 2026)

Mirum Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $642.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 45.01% year-over-year to $642.5 million; the TTM figure through Mar 2026 stood at $642.5 million (up 45.01% YoY), while the FY2025 annual figure was $523.1 million, up 18.19% from the prior year.
• Total Non-Current Liabilities was $642.5 million for Q1 2026 at Mirum Pharmaceuticals, up from $523.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $642.5 million in Q1 2026 to a low of $57.0 million in Q3 2022.
• Historically, Total Non-Current Liabilities has averaged $357.3 million across 5 years, with a median of $413.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities tumbled 68.09% in 2022, then soared 569.01% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $70.5 million in 2022, then surged by 458.87% to $394.1 million in 2023, then increased by 12.31% to $442.6 million in 2024, then gained by 18.19% to $523.1 million in 2025, then climbed by 22.82% to $642.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $642.5 million (Q1 2026), $523.1 million (Q4 2025), and $477.1 million (Q3 2025), per Business Quant data.